Receptor.AI is the first preclinical-stage company to develop a whole drug discovery platform around ultimate selectivity to cell- and tissue-specific protein isoforms, allele variants, inherited and cancer mutations. At Receptor.AI, we understand that precision and individualised medicine require a profound insight into the molecular distinctions between malfunctioning and normal proteins. In order to achieve the goal of ultra-selectivity to highly similar protein variants, we created a unique set of technologies with five levels of selectivity assessment for the candidate compounds. We are passionate about our approach and believe that it will transform drug development by making it more personalised and effective for patients than ever before.
Location: United States, Ohio, London
Employees: 11-50
Founded date: 2021
Mentions in press and media 7
| Date | Title | Description |
| 02.04.2025 | Receptor.AI and Ono Pharmaceutical Enter a Research Collaboration to Accelerate AI-Powered Drug Discovery | Receptor.AI and Ono Pharmaceutical enter a research collaboration to accelerate AI-powered drug discovery BOSTON, MA, UNITED STATES, April 2, 2025 /EINPresswire.com/ -- Receptor.AI, a leading preclinical TechBio company transforming drug di... |
| 24.02.2023 | A year on from Russia’s invasion, Ukrainian startups show astounding resilience | Today marks exactly one year since Russia’s illegal, unprovoked and brutal invasion of Ukraine. This week, a majority of the members of the United Nations reiterated its demand that Russia “immediately, completely and unconditionally withdr... |
| 15.12.2022 | The lipid membranes are druggable and available for AI-based drug design (acticle by Receptor.AI) | Figure 1. The scheme of water-soluble drug design module (above) and membranotropic drug design module (below) Figure 2. Development of bifunctional drugs. Figure 3. Synergistic double targeting of transmembrane proteins by separate water-s... |
| 12.12.2022 | Receptor.AI helps fight obesity by acting on the “sixth taste” receptors | Fighting obesity with selective taste receptors agonists CD36 and GPR120: absence of structure LONDON, UNITED KINGDOM, December 12, 2022 /EINPresswire.com/ -- A full text of the article can be found via the link: Obesity is one of the healt... |
| 28.11.2022 | DEL and AI: a marriage of convenience (article from Receptor.AI) | DNA-Encoded Libraries for novel Hit discovery (DEL first, AI second) DNA-Encoded Library selection for novel Hit/lead discovery (AI first, DEL second) The Architecture of fragment-based DTI for DEL activity prediction LONDON, LONDON, UNITED... |
| 14.08.2022 | Undruggable targets: the major challenge for modern drug discovery (report by Receptor.AI) | The overview of Receptor.AI’s approach to undruggable targets The AI approaches for beating undruggability LONDON, UNITED KINGDOM, August 14, 2022 /EINPresswire.com/ -- The most frightening word in modern drug discovery is “undruggable”. Th... |
| 14.08.2022 | RECEPTOR.AI introduces SaaS platform for rapid and precise drug design | Receptor.AI announces the latest version of our AI-accelerated SaaS platform to disrupt drug discovery. LONDON, UNITED KINGDOM, August 14, 2022 /EINPresswire.com/ -- Receptor.AI is delighted to announce the launch of the SaaS platform for A... |